The estimated Net Worth of Mark Anthony Mc Camish is at least $4.73 million dollars as of 28 December 2023. Mark Camish owns over 75,000 units of Rafael Inc stock worth over $103,219 and over the last 18 years Mark sold RFL stock worth over $4,630,844.
Sign up
Mark Camish RFL stock SEC Form 4 insiders trading
Mark has made over 11 trades of the Rafael Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Mark sold 75,000 units of RFL stock worth $1,089,750 on 28 December 2023.
The largest trade Mark's ever made was buying 171,000 units of Rafael Inc stock on 16 September 2020 worth over $984,960. On average, Mark trades about 18,290 units every 73 days since 2007. As of 28 December 2023 Mark still owns at least 67,025 units of Rafael Inc stock.
You can see the complete history of Mark Camish stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mark Camish's mailing address?
Mark's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Insiders trading at Rafael Inc
Over the last 7 years, insiders at Rafael Inc have traded over $423,229 worth of Rafael Inc stock and bought 3,338,367 units worth $11,056,239 . The most active insiders traders include Howard S Jonas, Mark Anthony Mc Camish et Plus, Llc I9. On average, Rafael Inc executives and independent directors trade stock every 87 days with the average trade being worth of $1,371,943. The most recent stock trade was executed by Howard S Jonas on 5 August 2022, trading 112,561 units of RFL stock currently worth $211,615.
What does Rafael Inc do?
we are a wholly owned subsidiary of rafael holdings focused on pipeline development
What does Rafael Inc's logo look like?
Complete history of Mark Camish stock trades at Avadel Pharmaceuticals plc, PDL Biopharma Inc et Rafael Inc
Rafael Inc executives and stock owners
Rafael Inc executives and other stock owners filed with the SEC include:
-
Menachem Ash,
President, General Counsel -
William Conkling,
Chief Exec. Officer -
David Polinsky,
Chief Financial Officer -
Howard S. Jonas,
Founder & Chairman -
David A. Polinsky Esq.,
Chief of Staff -
Howard Jonas,
Chairman of the Board, Chief Executive Officer -
Michael Weiss,
Independent Director -
Boris Pasche,
Independent Director -
Stephen Greenberg,
Lead Independent Director -
Joyce J. Mason Esq.,
Corp. Sec. -
Dr. Rick Ewing,
Head of Drug Discovery -
Gus Kodersha,
Chief Technical Operations Officer -
Barbara A. Ryan,
Investor Relations Officer -
Patrick Fabbio M.B.A.,
CFO & Pres -
Mary Margaret Huizinga,
Chief Devel. & Medical Officer -
John Goldberg,
CHIEF MEDICAL OFFICER -
William Conkling,
Chief Executive Officer -
Corp Idt,
10% owner -
Joyce J Mason,
-
Ashok D Marin,
Chief Legal Officer -
Mark Anthony Mc Camish,
Director -
Shannon Thyme Klinger,
Director -
Patrick Fabbio,
CFO & President -
Ameet Mallik,
Director -
Plus, Llc I9,
10% owner